Wells Fargo assumed coverage of Zymeworks (ZYME) with an Equal Weight rating and price target of $15, up from $14. The firm believes a positive outcome in the upcoming gastroesophageal adenocarcinoma readout is factored in at current share levels. Wells believes it is too early to assign much value to the company’s pipeline beyond zanidatamab.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Promising Early-Stage Data and Strategic Initiatives Drive Buy Rating for Zymeworks’ ZW191 Program
- Buy Rating for Zymeworks’ ZW191 Driven by Promising Efficacy and Favorable Safety Profile
- Zymeworks Reports Promising Phase 1 Results for ZW191 in Cancer Treatment
- Zymeworks reports preliminary results from Phase 1 study of ZW191
- Promising Early-Stage Data and Competitive Positioning Support Buy Rating for Zymeworks’ ADC Platform